A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Criteria: * Patients must have pathologically confirmed non-small cell lung cancer * Early Stage NSCLC Stage IA2 - IIA (tumor size \> 1cm and ≤ 5cm, N0M0), select IIB (tumor size \>5cm and ≤ 7cm, N0M0). Multiple (up to 2) primary lung cancers allowed. Isolated parenchymal recurrences (tumor size ≤ 7cm and up to 2 separate ipsilateral lesions) of initially TanyN0M0 disease. ° Note: The determination of two primary NSCLCs will be based on pathologic and genomic differentiation. * No known sensitizing EGFR or ALK alterations * Disease amenable to 3, 5 or 8 fraction SBRT as judged by treating radiation oncologist. Tumors that have extensive overlap with the mediastinum for which a more protracted radiotherapy course (i.e. 15 fraction) would be needed are excluded. * No primary tumor (Gross Target Volume, GTV) that contacts the esophagus * Unwilling to undergo surgical resection or ineligible for surgical resection as determined by review of a multidisciplinary team for surgical candida…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source